drugset / Trial / NCT04666714

Efficacy and Safety of Praga Formulation in the Treatment of Neuropathic Pain

NCT04666714

Phase 3 Recruiting 136 enrolled EMS
RandomizedParallel-groupDouble-blindTreatment

Summary

The purpose of this study is to evaluate the efficacy and safety of Praga formulation in the treatment of neuropathic pain.

Timeline

Start
2023-05-15
Primary completion
2025-09-30
Completion
2025-12-31

Drugs

EvaluationDrugModalityDoseRoute
Subject Praga formulation Unknown Oral
Comparator Pregabalin Small molecule 75 mg Oral
Comparator Pregabalin Small molecule 150 mg Oral

Indications